We stay close to our portfolio companies. Here's how they're doing.

Featured
Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv8
Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv8
MMI Wins FDA Clearance and Completes First U.S. Clinical Use of Robotic Microsurgical Dissection Instruments with Symani
MMI Wins FDA Clearance and Completes First U.S. Clinical Use of Robotic Microsurgical Dissection Instruments with Symani
Lynkuet™ (elinzanetant) approved in the EU for the treatment of moderate to severe vasomotor symptoms associated with menopause or endocrine therapy for breast cancer
Lynkuet™ (elinzanetant) approved in the EU for the treatment of moderate to severe vasomotor symptoms associated with menopause or endocrine therapy for breast cancer
MMI Receives IDE Approval from FDA for First Robotic Microsurgical Study in Alzheimer’s Patients
MMI Receives IDE Approval from FDA for First Robotic Microsurgical Study in Alzheimer’s Patients
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
NEUROMARK® Treatment for Chronic Rhinitis Demonstrates Durable 2-Year Clinical Benefits
NEUROMARK® Treatment for Chronic Rhinitis Demonstrates Durable 2-Year Clinical Benefits
MMI Completes World’s First Robotic Microsurgical Intracranial Brain Surgery
MMI Completes World’s First Robotic Microsurgical Intracranial Brain Surgery
Corteria Pharmaceuticals initiates Phase 2 trial in heart failure and Phase 1 trial in obesity with its first-in-class CRF2 agonists
Corteria Pharmaceuticals initiates Phase 2 trial in heart failure and Phase 1 trial in obesity with its first-in-class CRF2 agonists
First Patient Dosed in XyloCor Therapeutics’ Phase 2b EXACT-2 Trial Evaluating XC001 for the Treatment of Coronary Artery Disease
First Patient Dosed in XyloCor Therapeutics’ Phase 2b EXACT-2 Trial Evaluating XC001 for the Treatment of Coronary Artery Disease
Priothera Secures EUR1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program
Priothera Secures EUR1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program
Vivasure Medical Submits PMA Application for PerQseal® Elite and Secures Expanded Venous Indication in Europe
Vivasure Medical Submits PMA Application for PerQseal® Elite and Secures Expanded Venous Indication in Europe
Neurent Medical Announces 510(k) Clearance of its Next Generation NEUROMARK® System
Neurent Medical Announces 510(k) Clearance of its Next Generation NEUROMARK® System
Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen
Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen
Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML)
Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML)
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield
Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System
Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System
Neuromod Closes €10m Financing to Accelerate Commercialisation
Neuromod Closes €10m Financing to Accelerate Commercialisation
Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®
Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®
XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease
XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease
Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal® Large Hole Closure Device
Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal® Large Hole Closure Device
Mainstay Medical Announces New ICD-10 Diagnosis Code for Multifidus Dysfunction
Mainstay Medical Announces New ICD-10 Diagnosis Code for Multifidus Dysfunction
NEUROMARK® Treatment for Chronic Rhinitis Yields Significant Clinical Improvements
NEUROMARK® Treatment for Chronic Rhinitis Yields Significant Clinical Improvements
Lenire Controlled Clinical Trial Results Published in Nature Communications
Lenire Controlled Clinical Trial Results Published in Nature Communications
MMI Completes World’s First Robotic Preclinical Study in Neurosurgery with Symani® Surgical System
MMI Completes World’s First Robotic Preclinical Study in Neurosurgery with Symani® Surgical System
Mainstay Medical Announces Receipt of European and Australian Approvals of MRI Labeling on ReActiv8® Restorative Neurostimulation System
Mainstay Medical Announces Receipt of European and Australian Approvals of MRI Labeling on ReActiv8® Restorative Neurostimulation System
XyloCor Therapeutics and SmartCella Enter into License Agreement for Use of the Extroducer Infusion Catheter System to Administer Novel Gene Therapy XC001 to the Heart
XyloCor Therapeutics and SmartCella Enter into License Agreement for Use of the Extroducer Infusion Catheter System to Administer Novel Gene Therapy XC001 to the Heart
MMI Builds Global Momentum with Multiple Distribution Agreements and Regulatory Approvals
MMI Builds Global Momentum with Multiple Distribution Agreements and Regulatory Approvals
Neuromod's FDA-Approved Lenire Device Now a Treatment Option for 2.9 Million US Veterans with Tinnitus
Neuromod's FDA-Approved Lenire Device Now a Treatment Option for 2.9 Million US Veterans with Tinnitus
Neurent Medical Announces Publication of Positive Long-Term Results from Study on Chronic Rhinitis Treatment
Neurent Medical Announces Publication of Positive Long-Term Results from Study on Chronic Rhinitis Treatment
XyloCor Therapeutics Positive EXACT Phase 2 Data for XC001 Simultaneously Presented at SCAI 2024 Scientific Sessions and Published in Circulation: Cardiovascular Interventions
XyloCor Therapeutics Positive EXACT Phase 2 Data for XC001 Simultaneously Presented at SCAI 2024 Scientific Sessions and Published in Circulation: Cardiovascular Interventions